Crizotinib Effects on Creatinine and Non-Creatinine–Based Measures of Glomerular Filtration Rate

D. Ross Camidge, MD, PhD, Evelyn M. Brosnan, MD,* Chamath DeSilva, MD,† Phillip J. Koo, MD,‡ and Michel Chonchol, MD§*

Introduction: Rapid reductions in creatinine-based estimates of the glomerular filtration rate (GFR) have recently been reported secondary to crizotinib use. Whether these reflect drug-induced changes in the true GFR or the validity of creatinine as a measure of kidney function in the presence of crizotinib is unknown.

Methods: Two anaplastic lymphoma kinase–rearranged non–small-cell lung cancer patients (one with pre-existing renal impairment) were identified during periods of time on and off crizotinib. Creatinine- and iothalamate-based estimates of renal function were conducted in the presence and absence of crizotinib.

Results: Crizotinib is associated with both acute and chronic effects on kidney function. Chronic creatinine changes seem to reflect a true reduction in the GFR. In contrast, acute effects include a reduction in creatinine-based estimates of the GFR without a reduction in non-creatinine–based measurements (consistent with, e.g., an acute effect of crizotinib on creatinine secretion), in addition to some reduction in the true GFR (with this latter effect seeming to be more prominent in the presence of pre-existing renal impairment).

Conclusion: If crizotinib-associated changes in creatinine-based kidney function suggest a change in dosing with either crizotinib or concomitant medications that are renally excreted, use of a non-creatinine–based assessment of kidney function, such as iothalamate assessments, should be considered before making a final decision.

Key Words: Anaplastic lymphoma kinase, Crizotinib, Creatinine, Glomerular filtration rate.

(*J Thorac Oncol.* 2014;9: 1634–1637)

Crizotinib is a small-molecule, ATP-competitive, inhibitor of anaplastic lymphoma kinase (ALK), ROS1, and mesenchymal-epithelial transition (MET).[1–3] Known side effects include gastrointestinal disturbance, elevated transaminases, rapid reduction in free testosterone levels in the majority of men taking the drug, and asymptomatic bradycardia.[4–6] We recently reported apparent effects on kidney function as another side effect of crizotinib.[7] Specifically, crizotinib rapidly produces a mean 23.9% drop in the creatinine-derived estimated glomerular filtration rate (eGFR) according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) calculation that could not be accounted for by dehydration, by tumor lysis, or by the use of concomitant known nephrotoxic drugs or intravenous contrast.[7–9] The majority of changes in eGFR occurs within 2 weeks of starting the drug and then plateaus. On cessation of dosing, eGFR was recoverable to 84% of baseline values or above in all patients. Based on these data, we rejected the idea that crizotinib was directly nephrotoxic. Instead, within our initial report, we raised two possible mechanistic hypotheses: either crizotinib was somehow interfering with a proportion of kidney function or it was altering the validity of creatinine as a measure of kidney function. This latter mechanism could occur, for example, through crizotinib competing with creatinine for secretion into the urine within the renal tubules, as has been described for some other drugs.[10,11] Here, we present matched creatinine-based estimates of eGFR and direct measurements of the GFR using urinary creatinine clearance and/or iothalamate assessments in two patients both on and off crizotinib to inform this debate.[12]

PATIENTS AND METHODS

Two ALK-rearranged non–small-cell lung cancer patients (one with pre-existing renal impairment) were prospectively identified during periods of time on and off crizotinib. Vital signs and creatinine- and iothalamate-based estimates of renal function were conducted in the presence and absence of crizotinib. The data were retrieved from patient electronic medical records in accordance with University of Colorado Institutional Review Board–approved protocol 09-018.

RESULTS

Case 1

A 53-year-old white male patient with stage IV adenocarcinoma of the lung developed chronic renal impairment secondary to initial chemotherapy exposure (six cycles of carboplatin and paclitaxel, followed by five cycles of cisplatin and pemetrexed and 12 cycles of maintenance pemetrexed). He initially had a complete response to the chemotherapy, but

*Division of Medical Oncology, Department of Medicine, University of Colorado, Aurora, CO; †Department of Oncology, Colorado Permanente Medical Group, Lafayette, CO; and ‡Department of Radiology and §Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado, Aurora, CO.

Supported by University of Colorado Specialized Program of Research Excellence (SPORE) in lung cancer (P50CA058187) and the University of Colorado Comprehensive Cancer Center Support grant (P30CA046934).

Address for correspondence: D. Ross Camidge, MD, PhD, University of Colorado Comprehensive Cancer Center, 1665 North Aurora Court, Mail Stop F-704, ACP Room 5327, Aurora, CO 80045. E-mail: Ross.camidge@ucdenver.edu

10.1097/JTO.0000000000000321

ISSN: 1556-0864/14/0911-1634

18 months after the end of the chemotherapy his disease progressed. At this point, he had been identified as ALK positive and was started on crizotinib, at which point his pretreatment creatinine was 2.05 mg/dl. He had a good radiographic response but was deemed intolerant of the drug due to recurrent elevations in serum creatinine associated with its use at all doses from 250 mg twice daily to 200 mg on alternate days, and crizotinib was discontinued.[7] His disease remained largely in remission off crizotinib, with isolated areas of growth being controlled with stereotactic body radiation therapy. When further tumor growth manifested in his liver, due to our increased awareness of the potential reversibility and limited cumulative effect of crizotinib on renal function, it was considered safe to rechallenge with crizotinib 250 mg twice daily, in conjunction with increased vigilance of his renal function. Three days before recommencing crizotinib, his blood pressure and heart rate were 123/75 and 57 beats per minute (bpm), respectively. His serum creatinine was 2.09 mg/dl, his eGFR calculated using the CKD-EPI prediction equation was 34 ml/min per 1.73 m^2, and his creatinine clearance measured through a 24-hour urine collection was 47.38 ml/min per 1.73 m^2 (1426 mg creatinine/day in urine). After being on crizotinib for 15 days, his serum creatinine was 2.64 mg/dl, his eGFR calculated using the CKD-EPI equation was 26 ml/min per 1.73 m^2, and his creatinine clearance measured through a 24-hour urine collection was 34.90 ml/min per 1.73 m^2 (1307 mg creatinine/day in urine). Urine microscopy was unremarkable and did not show any evidence of acute tubular necrosis (i.e., granular casts or renal tubular epithelial cells). Vital signs were available 30 days after being on crizotinib and showed a blood pressure and heart rate of 118/68 and 43 bpm, respectively. He had a complete metabolic and radiographic response on his first positron emission tomography/computed tomography scan performed after 6 weeks of therapy.

After approximately 5 months of therapy, his creatinine was recorded as 3.22 mg/dl, with a CKD-EPI eGFR of 20 ml/min per 1.73 m^2, and the decision was made to discontinue his crizotinib. His scans still showed no evidence of active disease, although his carcinoembryonic antigen (CEA) had increased from 18.6 at baseline to 49.9 ng/ml. His blood pressure and heart rate at this point were 115/68 and 46 bpm, respectively. On the last day of dosing with crizotinib, there had been some spontaneous improvement in his apparent renal function compared with the recordings 6 days beforehand. Specifically, his creatinine was 2.61 mg/dl, with a CKD-EPI eGFR of 26 ml/min per 1.73 m^2. An iothalamate assessment obtained on the same day showed a GFR of 37.3 ml/min per 1.73 m^2. He discontinued his crizotinib, and 23 days later his creatinine had fallen to 2.14 mg/dl, his CKD-EPI eGFR had increased to 33 ml/min per 1.73 m^2, his CEA had fallen to 24.9 ng/ml, and a repeat iothalamate assessment showed his GFR to have increased to 70.7 ml/min per 1.73 m^2 (Figs. 1 and 2*A*). Thirty days after crizotinib, his blood pressure and heart rate were 108/65 and 64 bpm, respectively. The patient was not on any known nephrotoxic medication, and, apart from the cessation of his crizotinib, there were no other changes in medication use during this time.

Case 2

A 70-year-old white male with stage IV adenocarcinoma of the lung was initially treated with carboplatin, pemetrexed, and zoledronic acid for four cycles. Subsequent molecular testing confirmed him to be ALK positive by fluorescence in situ hybridization analysis, and he commenced crizotinib at 250 mg twice daily. After 25 months of therapy, he developed oligoprogression in his sacrum and proximal left humerus and was treated with stereotactic body irradiation.[13] After 4 months, he developed decreased vision in his right eye and was found to have a new retinal lesion and referred again for radiation therapy. A magnetic resonance imaging of his brain was unremarkable at the time.

At the start of his initial crizotinib therapy, his blood pressure and heart rate were 168/70 and 87 bpm, respectively,



FIGURE 1. Changes in serum creatinine and carcinoembryonic antigen (CEA) levels on commencement and cessation of crizotinib treatment in a patient with pre-existing renal impairment. Units of CEA (ng/ml) and creatinine (mg/dl) are shown on the *y* axis and dates of measurements on the *x* axis. The green and blue horizontal lines represent the lower and upper limits of normal of each assay, respectively. Of note, CEA is known to be renally excreted, and the patient had a complete metabolic and radiographic response on positron emission tomography/computed tomography scanning that occurred rapidly and persisted during this period of time, despite the changes in CEA.

